Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
US9180191B2 · kind B2 · utility
8Cited by
10References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2010 |
| Grant date | Nov 10, 2015 |
| Priority date | — |
| Expiry date | Oct 15, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns methods of treating suicidal ideation or behavior in a subject in need thereof, comprising decreasing endogenous nicotinic acetylcholine receptor (nAChR) activity in the subject; therapeutic packages for treating suicidal ideation or behavior; and methods for determining the efficacy of a treatment for suicidal ideation or behavior. In some embodiments, the treatment methods comprise administering to the subject an effective amount of an inhibitor of a nAChR, such as a lithium compound, mecamylamine, clozapine, or asenapine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.